Hypocalcaemia in patients with metastatic bone disease treated with denosumab

European Journal of Cancer

Volumn 51, Issue 13, 2015, Pages 1812-1821

  Body, Jean Jacques ^a   Bone, Henry G ^b   De Boer, Richard H ^c   Stopeck, Alison ^d   Van Poznak, Catherine ^e   Damião, Ronaldo ^f   Fizazi, Karim ^g   Henry, David H ^h   Ibrahim, Toni ⁱ   Lipton, Allan ^j   Saad, Fred ^k   Shore, Neal ^l   Takano, Toshimi ^m   Shaywitz, Adam J ^n,o   Wang, Huei ⁿ   Bracco, Oswaldo L ^n,p   Braun, Ada ^n,q   Kostenuik, Paul J ⁿ  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b Michigan Bone and Mineral Clinic   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d Stony Brook School of Dental Medicine   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h PENNSYLVANIA HOSPITAL   (United States)

ⁱ DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l Carolina Urologic Research Center   (United States)

^m TORANOMON HOSPITAL   (Japan)

ⁿ AMGEN INC   (United States)

^o BIOMARIN PHARMACEUTICAL INC   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

^q Pharmaceutical Group Biothera   (United States)

more..

Author keywords

Bone metastasis; Denosumab; Hypocalcaemia; Risk factors; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CREATININE; DENOSUMAB; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

AGED; ARTICLE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; FEMALE; HUMAN; HYPOCALCEMIA; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMALL CELL LUNG CANCER; VITAMIN SUPPLEMENTATION; BLOOD; BONE NEOPLASMS; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; SECONDARY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

ANTINEOPLASTIC AGENTS; BIOMARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CALCIUM; CLINICAL TRIALS, PHASE III AS TOPIC; DENOSUMAB; DIPHOSPHONATES; HUMANS; HYPOCALCEMIA; IMIDAZOLES; INCIDENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

EID: 84938740077     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.05.016     Document Type: Article

References (34)

1. J.J. Body Denosumab for the management of bone disease in patients with solid tumors Expert Rev Anticancer Ther 12 2012 307 322
2. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
3. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 2006 6243s 6249s
4. D.I. Jodrell, T.J. Iveson, and I.E. Smith Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate Lancet 1 1987 622
5. A. Lipton, K. Fizazi, A.T. Stopeck, and et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials Eur J Cancer 48 2012 3082 3092
6. B.A. Gartrell, R.E. Coleman, K. Fizazi, and et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer Eur Urol 65 2014 278 286
7. M.R. Smith, F. Saad, S. Oudard, and et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time J Clin Oncol 31 2013 3800 3806
8. J.L. Gulley, S. Wu, P.M. Arlen, and W.L. Dahut Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases Clin Genitourin Cancer 5 2007 403 405
9. C. Champallou, J.P. Basuyau, C. Veyret, and et al. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports J Pain Symptom Manage 25 2003 185 190
10. P.L. Riches, E. McRorie, W.D. Fraser, C. Determann, R. van't Hof, and S.H. Ralston Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin N Engl J Med 361 2009 1459 1465
11. M. Hanamura, T. Iwamoto, N. Soga, Y. Sugimura, and M. Okuda Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor Biol Pharm Bull 33 2010 721 724
12. A.T. Stopeck, A. Lipton, J.J. Body, and et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
13. K. Fizazi, M. Carducci, M. Smith, and et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
14. D.H. Henry, L. Costa, F. Goldwasser, and et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125 1132
15. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). < http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf >; 2006 [accessed 06.06.14].
16. S. Morony, K. Warmington, S. Adamu, and et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy Endocrinology 146 2005 3235 3243
17. J.J. Body, A. Lipton, J. Gralow, and et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure J Bone Miner Res 25 2010 440 446
18. G. Liamis, H.J. Milionis, and M. Elisaf A review of drug-induced hypocalcemia J Bone Miner Metab 27 2009 635 642
19. R.R. Recker, E.M. Lewiecki, P.D. Miller, and J. Reiffel Safety of bisphosphonates in the treatment of osteoporosis Am J Med 122 2009 S22 S32
20. M. Zuradelli, G. Masci, G. Biancofiore, and et al. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid Oncologist 14 2009 548 556
21. A. Lipton, G.G. Steger, J. Figueroa, and et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 2007 4431 4437
22. K. Fizazi, L. Bosserman, G. Gao, T. Skacel, and R. Markus Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial J Urol 182 2009 509 515 [discussion 15-6]
23. W.X. Qi, F. Lin, A.N. He, L.N. Tang, Z. Shen, and Y. Yao Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies Curr Med Res Opin 29 2013 1067 1073
24. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P.T. Leese, and C.R. Dunstan The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 2001 348 360
25. N.M. Maalouf, H.J. Heller, C.V. Odvina, P.J. Kim, and K. Sakhaee Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature Endocr Pract 12 2006 48 53
26. B.B. McCormick, J. Davis, and K.D. Burns Severe hypocalcemia following denosumab injection in a hemodialysis patient Am J Kidney Dis 60 2012 626 628
27. C.J. Rosen, and S. Brown Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency N Engl J Med 348 2003 1503 1504
28. H.E. Whitson, B. Lobaugh, and K.W. Lyles Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone Bone 39 2006 954 958
29. G.A. Block, H.G. Bone, L. Fang, E. Lee, and D. Padhi A single-dose study of denosumab in patients with various degrees of renal impairment J Bone Miner Res 27 2012 1471 1479
30. P.J. Kostenuik, S.Y. Smith, R. Samadfam, J. Jolette, L. Zhou, and M.S. Ominsky Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys J Bone Miner Res 30 2015 657 669
31. H.M. Frost Some ABCs of skeletal pathophysiology. III: Bone balance and the delta B.BMU Calcif Tissue Int 45 1989 131 133
32. P.J. Kostenuik, S.Y. Smith, J. Jolette, J. Schroeder, I. Pyrah, and M.S. Ominsky Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody Bone 49 2011 151 161
33. J.C. Gallagher, C.M. Jerpbak, W.S. Jee, K.A. Johnson, H.F. DeLuca, and B.L. Riggs 1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis Proc Natl Acad Sci USA 79 1982 3325 3329
34. J.J. Body, and R. Bouillon Emergencies of calcium homeostasis Rev Endocr Metab Disord 4 2003 167 175